$CRKN
Crown Electrokinetics Corp. Stock $crkn

$crkn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000176169624000018 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$4.648M	$682.0K	$22.00K
YoY Change	12462.16%	3000.0%
Cost Of Revenue	$4.039M	$1.636M	$31.00K
YoY Change	17460.87%	5177.42%
Gross Profit	$609.0K	-$954.0K	-$9.000K
YoY Change	4250.0%	10500.0%
Gross Profit Margin	13.1%	-139.88%	-40.91%
Selling, General & Admin	$4.187M	$1.783M	$3.576M
YoY Change	-5.04%	-50.14%	3.03%
% of Gross Profit	687.52%
Research & Development	$1.111M	$756.0K	$541.0K
YoY Change	126.73%	39.74%	-50.64%
% of Gross Profit	182.43%
Depreciation & Amortization	$100.0K	$212.0K	$128.0M
YoY Change	-47.92%	-99.83%	119526.17%
% of Gross Profit	16.42%
Operating Expenses	$5.298M	$2.539M	$4.117M
YoY Change	8.14%	-38.33%	-9.85%
Operating Profit	-$4.908M	-$3.705M	-$4.126M
YoY Change	0.47%	-10.2%	-9.66%
Interest Expense	-$145.0K	$860.0K	$2.017M
YoY Change	-105.78%	-57.36%	-67333.33%
% of Operating Profit
Other Income/Expense, Net	-$121.0K	-$907.0K	$1.826M
YoY Change	-98.74%	-149.67%	-60966.67%
Pretax Income	-$5.029M	-$4.612M	-$2.300M
YoY Change	-65.36%	100.52%	-49.67%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.029M	-$4.612M	-$2.300M
YoY Change	-65.36%	100.52%	-49.67%
Net Earnings / Revenue	-108.2%	-676.25%	-10454.55%
Basic Earnings Per Share	-$5.89	-$0.13	-$4.88
Diluted Earnings Per Share	-$5.89	-$0.13	-$0.08
COMMON SHARES
Basic Shares Outstanding	281.9M shares	51.70M shares	43.69M shares
Diluted Shares Outstanding	1.740M shares	36.68M shares	29.70M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.990M	$290.0K	$2.138M
YoY Change	10983.33%	-86.44%	-14.92%
Cash & Equivalents	$4.000M	$300.0K	$2.138M
Short-Term Investments
Other Short-Term Assets	$30.00K	$351.0K	$97.00K
YoY Change	-16.67%	261.86%	-87.47%
Inventory
Prepaid Expenses
Receivables	$3.400M	$776.0K
Other Receivables	$211.0K	$576.0K
Total Short-Term Assets	$9.174M	$2.455M	$2.861M
YoY Change	1058.33%	-14.19%	-12.96%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.012M	$3.036M	$2.528M
YoY Change	27.3%	20.09%	-17.63%
Goodwill			$652.0K
YoY Change
Intangibles			$1.744M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$160.0K	$165.0K	$213.0K
YoY Change	384.85%	-22.54%	-47.01%
Total Long-Term Assets	$6.826M	$6.422M	$15.11M
YoY Change	-39.89%	-57.49%	191.3%
TOTAL ASSETS
Total Short-Term Assets	$9.174M	$2.455M	$2.861M
Total Long-Term Assets	$6.826M	$6.422M	$15.11M
Total Assets	$16.00M	$8.877M	$17.97M
YoY Change	31.72%	-50.6%	112.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.215M	$2.297M	$1.146M
YoY Change	21.57%	100.44%	247.27%
Accrued Expenses	$898.0K	$962.0K	$230.0K
YoY Change	120.1%	318.26%	-61.47%
Deferred Revenue	$1.300M	$1.260M
YoY Change
Short-Term Debt	$0.00	$93.00K	$4.710M
YoY Change	-100.0%	-98.03%	58775.0%
Long-Term Debt Due	$636.0K
YoY Change
Total Short-Term Liabilities	$5.744M	$5.261M	$9.016M
YoY Change	-20.61%	-41.65%	864.28%
LONG-TERM LIABILITIES
Long-Term Debt	$296.0K	$328.0K	$0.00
YoY Change
Other Long-Term Liabilities	$1.178M	$970.0K	$1.208M
YoY Change	231.83%	-19.7%	-33.41%
Total Long-Term Liabilities	$1.474M	$1.298M	$1.208M
YoY Change	315.21%	7.45%	-33.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.744M	$5.261M	$9.016M
Total Long-Term Liabilities	$1.474M	$1.298M	$1.208M
Total Liabilities	$7.218M	$6.559M	$10.22M
YoY Change	-4.9%	-35.85%	271.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$126.6M	-$121.6M	-$90.31M
YoY Change	20.77%	34.65%
Common Stock	$0.00	$10.00K	$4.000K
YoY Change	-100.0%	150.0%
Preferred Stock			$4.350M
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.782M	$2.318M	$7.744M
YoY Change
Total Liabilities & Shareholders Equity	$16.00M	$8.877M	$17.97M
YoY Change	31.72%	-50.6%	112.06%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$5.029M	-$4.612M	-$2.300M
YoY Change	-65.36%	100.52%	-49.67%
Depreciation, Depletion And Amortization	$100.0K	$212.0K	$128.0M
YoY Change	-47.92%	-99.83%	119526.17%
Cash From Operating Activities	-$6.176M	-$2.700M	-$4.728M
YoY Change	68.84%	-42.89%	33.11%
INVESTING ACTIVITIES
Capital Expenditures	-$7.000K	$63.00K	$435.0K
YoY Change	-102.62%	-85.52%	-769.23%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$645.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$7.000K	-$63.00K	-$1.080M
YoY Change	-102.58%	-94.17%	1561.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	9.869M	$1.971M	$7.125M
YoY Change	441.06%	-72.34%
NET CHANGE
Cash From Operating Activities	-6.176M	-$2.700M	-$4.728M
Cash From Investing Activities	7.000K	-$63.00K	-$1.080M
Cash From Financing Activities	9.869M	$1.971M	$7.125M
Net Change In Cash	3.700M	-$769.0K	$1.317M
YoY Change	-275.77%	-158.39%
FREE CASH FLOW
Cash From Operating Activities	-$6.176M	-$2.700M	-$4.728M
Capital Expenditures	-$7.000K	$63.00K	$435.0K
Free Cash Flow	-$6.169M	-$2.763M	-$5.163M
YoY Change	57.17%	-46.48%	48.06%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.01667
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	281930398	shares
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value
CY2024Q1	dei	Trading Symbol TradingSymbol	CRKN
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	290000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	813000	usd
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	576000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	2455000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1870000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3036000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3129000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1326000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1382000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1533000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1701000	usd
CY2024Q1	us-gaap	Deferred Costs DeferredCosts	362000	usd
CY2023Q4	us-gaap	Deferred Costs DeferredCosts	1306000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	165000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	139000	usd
CY2024Q1	us-gaap	Assets Assets	8877000	usd
CY2023Q4	us-gaap	Assets Assets	9527000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2297000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1500000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	962000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1190000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	606000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	655000	usd
CY2024Q1	crkn	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	23000	usd
CY2023Q4	crkn	Warrants And Rights Outstanding Current WarrantsAndRightsOutstandingCurrent	0	usd
CY2024Q1	us-gaap	Notes Payable Current NotesPayableCurrent	93000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	429000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1260000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	usd
CY2024Q1	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	20000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	2000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	5261000	usd
CY2024Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	328000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	950000	usd
CY2024Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	20000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	2000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4850000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	800000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25744158	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	7000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	121665000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116995000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4677000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9527000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1636000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	756000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	541000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1783000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3394000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3705000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4126000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	860000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2017000	usd
CY2024Q1	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	0	usd
CY2023Q1	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2024Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	0	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	23000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5606000	usd
CY2024Q1	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	0	usd
CY2023Q1	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-117000	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	24000	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	1206000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-907000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1826000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4612000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2300000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4612000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2300000	usd
CY2024Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	0	usd
CY2023Q1	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	6000	usd
CY2024Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4895000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2416000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.88
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36675540	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36675540	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	494918	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	494918	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4677000	usd
CY2024Q1	crkn	Stock Issuance Of Common Stockequity Line Of Credit Net Of Offering Costs StockIssuanceOfCommonStockequityLineOfCreditNetOfOfferingCosts	1391000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	588000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	274000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4612000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2318000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	530000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2062000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	516000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	298000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2107000	usd
CY2023Q1	crkn	Stock Issued During Period Value Issuance Of Series E Preferred Stock In Connection With Loc StockIssuedDuringPeriodValueIssuanceOfSeriesEPreferredStockInConnectionWithLOC	4350000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	181000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2300000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7744000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4612000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2300000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	274000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	181000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	212000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	182000	usd
CY2024Q1	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	0	usd
CY2023Q1	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	23000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5606000	usd
CY2024Q1	crkn	Gain On Issuance Of Convertible Note GainOnIssuanceOfConvertibleNote	0	usd
CY2023Q1	crkn	Gain On Issuance Of Convertible Note GainOnIssuanceOfConvertibleNote	64000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	374000	usd
CY2024Q1	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	0	usd
CY2023Q1	crkn	Change In Fair Value Of Notes ChangeInFairValueOfNotes	-117000	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	944000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1635000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	168000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	133000	usd
CY2024Q1	us-gaap	Interest Expense Other InterestExpenseOther	0	usd
CY2023Q1	us-gaap	Interest Expense Other InterestExpenseOther	1206000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	111000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	161000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	693000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	576000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	1260000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	797000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	125000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-228000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-920000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-171000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-134000	usd
CY2024Q1	crkn	Increase Decrease In Warranty Customer Liability IncreaseDecreaseInWarrantyCustomerLiability	-36000	usd
CY2023Q1	crkn	Increase Decrease In Warranty Customer Liability IncreaseDecreaseInWarrantyCustomerLiability	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2677000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4728000	usd
CY2024Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	0	usd
CY2023Q1	us-gaap	Payments To Acquire Businesses And Interest In Affiliates PaymentsToAcquireBusinessesAndInterestInAffiliates	645000	usd
CY2024Q1	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	63000	usd
CY2023Q1	us-gaap	Payments To Acquire Equipment On Lease PaymentsToAcquireEquipmentOnLease	435000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-63000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1080000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2062000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	588000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2107000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	2000000	usd
CY2024Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	970000	usd
CY2024Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	8000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	14000	usd
CY2024Q1	crkn	Proceeds From The Issuance Of Common Stock In Connection With Equity Line Of Credit Net Of Offering ProceedsFromTheIssuanceOfCommonStockInConnectionWithEquityLineOfCreditNetOfOffering	1391000	usd
CY2023Q1	crkn	Proceeds From The Issuance Of Common Stock In Connection With Equity Line Of Credit Net Of Offering ProceedsFromTheIssuanceOfCommonStockInConnectionWithEquityLineOfCreditNetOfOffering	0	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1971000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7125000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-769000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1317000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1059000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	821000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	290000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2138000	usd
CY2024Q1	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023Q1	us-gaap	Stock Issued1 StockIssued1	4350000	usd
CY2024Q1	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes	0	usd
CY2023Q1	crkn	Issuance Of Common Stock In Connection With Conversion Of Notes IssuanceOfCommonStockInConnectionWithConversionOfNotes	516000	usd
CY2024Q1	crkn	Commitment To Issue Shares Of Common Stock In Connection With March Waiver Agreement CommitmentToIssueSharesOfCommonStockInConnectionWithMarchWaiverAgreement	0	usd
CY2023Q1	crkn	Commitment To Issue Shares Of Common Stock In Connection With March Waiver Agreement CommitmentToIssueSharesOfCommonStockInConnectionWithMarchWaiverAgreement	298000	usd
CY2024Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	0	usd
CY2023Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6000	usd
CY2024Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	156000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	8000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-121600000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	300000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4600000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2700000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed financial statements in conformity with GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenue and expenses during the reporting periods. Accounting estimates and assumptions are inherently uncertain. Management bases its estimates and assumptions on current facts, historical experience and various other factors believed to be reasonable under the circumstances. Actual results could differ materially and adversely from these estimates. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include, but not limited to, valuation of its business combination, estimated fair value of convertible notes, estimated fair value of warrant liability, Series F/F-1/F-2 preferred stock, stock option awards for stock-based compensation and operating lease right-of-use assets and liabilities.</span></div>
CY2024Q1	crkn	Percentage Of Payment Invoices PercentageOfPaymentInvoices	0.05
CY2024Q1	us-gaap	Revenues Revenues	700000	usd
CY2023Q1	us-gaap	Revenues Revenues	22000	usd
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q3	crkn	Number Of Purchase Order Warrants NumberOfPurchaseOrderWarrants	2	reportingunit
CY2024Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	100000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5935805	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11851544	shares
CY2024Q1	crkn	Warranty Period WarrantyPeriod	P2Y
CY2024Q1	us-gaap	Product Warranty Expense ProductWarrantyExpense	36000	usd
CY2023Q1	us-gaap	Product Warranty Expense ProductWarrantyExpense	0	usd
CY2024Q1	crkn	Percentage Of Retainage Payments Withheld PercentageOfRetainagePaymentsWithheld	0.05
CY2024Q1	crkn	Retainage Receivable RetainageReceivable	100000	usd
CY2023Q4	crkn	Retainage Receivable RetainageReceivable	0	usd
CY2023Q1	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	655000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3036000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3129000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	100000	usd
CY2024Q1	crkn	Prepaid License Fees PrepaidLicenseFees	114000	usd
CY2023Q4	crkn	Prepaid License Fees PrepaidLicenseFees	158000	usd
CY2024Q1	crkn	Prepaid Professional Fees PrepaidProfessionalFees	142000	usd
CY2023Q4	crkn	Prepaid Professional Fees PrepaidProfessionalFees	53000	usd
CY2024Q1	us-gaap	Prepaid Insurance PrepaidInsurance	60000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	26000	usd
CY2024Q1	crkn	Prepaid Hudson Warrant PrepaidHudsonWarrant	86000	usd
CY2023Q4	crkn	Prepaid Hudson Warrant PrepaidHudsonWarrant	86000	usd
CY2024Q1	us-gaap	Prepaid Rent PrepaidRent	60000	usd
CY2023Q4	us-gaap	Prepaid Rent PrepaidRent	277000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	351000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	128000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	813000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	728000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4111000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4048000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1075000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	919000	usd
CY2024Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1800000	usd
CY2023Q4	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1800000	usd
CY2024Q1	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2023Q4	crkn	Finite Lived Intangible Assets Research License Gross FiniteLivedIntangibleAssetsResearchLicenseGross	375000	usd
CY2024Q1	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	4000	usd
CY2023Q4	us-gaap	Finite Lived Customer Relationships Gross FiniteLivedCustomerRelationshipsGross	4000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2179000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2179000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	853000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	797000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1326000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1382000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	179000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	234000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	197000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	194000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	195000	usd
CY2024Q1	crkn	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	327000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1326000	usd
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2024Q1	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Gross DebtIssuanceCostsLineOfCreditArrangementsGross	10647000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Gross DebtIssuanceCostsLineOfCreditArrangementsGross	10647000	usd
CY2024Q1	us-gaap	Accumulated Amortization Of Debt Issuance Costs Line Of Credit Arrangements AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements	10285000	usd
CY2023Q4	us-gaap	Accumulated Amortization Of Debt Issuance Costs Line Of Credit Arrangements AccumulatedAmortizationOfDebtIssuanceCostsLineOfCreditArrangements	9341000	usd
CY2024Q1	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	362000	usd
CY2023Q4	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	1306000	usd
CY2024Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	118000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	112000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	700000	usd
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1000000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	96000	usd
CY2023Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	51000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	27000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	962000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1190000	usd
CY2024Q1	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P0Y9M18D
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	776000	usd
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	83000	usd
CY2024Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	1300000	usd
CY2024Q1	crkn	Revenue From Contract With Customer Contract Price Advances Payments Collected RevenueFromContractWithCustomerContractPriceAdvancesPaymentsCollected	1300000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2300000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	93000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	65000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	60000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	60000	usd
CY2024Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	143000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	421000	usd
CY2024Q1	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	23000	usd
CY2023Q3	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	400000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	crkn	Aggregate Amount AggregateAmount	50000000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.0499
CY2024Q1	crkn	Purchase Price Of Common Stock Percentage PurchasePriceOfCommonStockPercentage	0.970
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	382779	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	65.04
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y1M6D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.09
CY2024Q1	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y10M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	0	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	632779	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	39.38
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	176728	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	138.32
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	250000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.957
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.049
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	274000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	181000	usd
CY2023Q4	crkn	Share Based Compensations Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationsArrangementByShareBasedPaymentAwardWarrantsOutstanding	1760095	shares
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingWeightedAverageExercisePrice	18.96
CY2023Q4	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Warrant Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantOutstandingWeightedAverageRemainingContractualTerm2	P4Y4M24D
CY2023Q4	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingIntrinsicValue	0	usd
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrants Issued ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsIssued	750000	shares
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Issued Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedWeightedAverageExercisePrice	0.09
CY2024Q1	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Options Issued Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedWeightedAverageRemainingContractualTerm	P4Y10M24D
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Issued In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardIssuedInPeriodGrantDateIntrinsicValue	0	usd
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrants Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercised	0	shares
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Exercised Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisedWeightedAverageExercisePrice	0
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisesInPeriodTotalIntrinsicValue	0	usd
CY2024Q1	crkn	Share Based Compensations Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationsArrangementByShareBasedPaymentAwardWarrantsOutstanding	2510095	shares
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingWeightedAverageExercisePrice	14.01
CY2024Q1	crkn	Sharebased Compensation Arrangement By Sharebased Payment Award Warrant Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardWarrantOutstandingWeightedAverageRemainingContractualTerm2	P4Y2M12D
CY2024Q1	crkn	Share Based Compensation Arrangement By Share Based Payment Award Warrant Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	471000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	190000	usd
CY2024Q1	us-gaap	Variable Lease Cost VariableLeaseCost	0	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	58000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	471000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	248000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	484000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	192000	usd
CY2024Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1146000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y8M12D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.120
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	606000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	578000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	478000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	240000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1902000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	346000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1556000	usd
CY2024Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2024Q1	us-gaap	Revenues Revenues	682000	usd
CY2023Q1	us-gaap	Revenues Revenues	22000	usd
CY2024Q1	us-gaap	Revenues Revenues	682000	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	1636000	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	-954000	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	212000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	756000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1783000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3705000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	860000	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	23000	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	24000	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-907000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4612000	usd
CY2023Q1	us-gaap	Revenues Revenues	22000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	31000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-9000	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	182000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	541000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3394000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4126000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	2017000	usd
CY2023Q1	crkn	Loss On Extinguishment Of Warrant Liability LossOnExtinguishmentOfWarrantLiability	504000	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	64000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-5606000	usd
CY2023Q1	crkn	Change In Fair Value Of Notes1 ChangeInFairValueOfNotes1	-117000	usd
CY2023Q1	crkn	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	0	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	1206000	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1826000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2300000	usd
CY2024Q1	us-gaap	Other Assets OtherAssets	165000	usd
CY2023Q1	us-gaap	Other Assets OtherAssets	213000	usd
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
R61.htm	Edgar Link	pending
crkn-20240331.htm	Edgar Link	pending
crkn-20240331.xsd	Edgar Link	pending
crkn-20240331xex311.htm	Edgar Link	pending
crkn-20240331xex312.htm	Edgar Link	pending
crkn-20240331xex321.htm	Edgar Link	pending
crkn-20240331xex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
crkn-20240331_cal.xml	Edgar Link	unprocessable
crkn-20240331_lab.xml	Edgar Link	unprocessable
crkn-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
crkn-20240331_htm.xml	Edgar Link	completed
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
0001761696-24-000018-index-headers.html	Edgar Link	pending
0001761696-24-000018-index.html	Edgar Link	pending
0001761696-24-000018.txt	Edgar Link	pending
0001761696-24-000018-xbrl.zip	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
crkn-20240331_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRKN
Crown Electrokinetics Corp. Stock $crkn

2024 Q2 Form 10-Q Financial Statement

#000176169624000018 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN Crown Electrokinetics Corp. Stock $crkn

2024 Q2 Form 10-Q Financial Statement

#000176169624000018 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRKN
Crown Electrokinetics Corp. Stock $crkn